Attorney's Docket No. 049542/283879

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Wilson et al.

Confirmation No.: 9724

10/780,296

Group Art Unit: 1624

February 17, 2004

Examiner:

M. Berch

A₁ ADENOSINE RECEPTOR ANTAGONISTS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 June 6, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449 along with a copy of any cited foreign patent documents and non-patent literature documents in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By identifying the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead identifying the listed documents for the sake of full disclosure.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

A check for the \$180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 16-0605.

06/08/2006 MAHMED1 00000013 10780296

02 FC:1806

180.00 OP

Respectfully submitted,

Jeffrey W. Childers

Registration No. 58,126

Customer No. 00826 ALSTON & BIRD LLP Bank of America Plaza

101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200 Fax Raleigh Office (919) 862-2260

"Express Mail" mailing label number EV 387075966 US Date of Deposit June 6, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria,

22313-1450

		01	10			
Substitute fo	or form 1449/P	fo		Complete if Known		
(Revised 07	/2005)	JUN 0 6	5000 m	Application Number	10/780,296	
INEOD				Filing Date	February 17, 2004	
INFOR		VELSCLO:		First Named Inventor	Wilson	
INFORMATION DISCLOSUS STATEMENT BY STATEMENT BY				Group Art Unit	Art Unit 1624	
(L	lse as many she	ets as necessary)		Examiner Name	M. Berch	
Sheet	1	of	3	Attorney Docket Number	049542/283879	

			U.S.	PATENT I	OC	UMENTS		
Examiner Initials*	Cite No.	<u>Document Number</u> Number - Kind Code (if known)		lication Date I-DD-YYYY		Name of Patentee or Applicant of Cited Document	Pages, Columns, Relevant Passages of Appe	Relevant Figures
	1	4,879,296	11-07-1989			Daluge et al.		
	2	5,290,782	3-01	3-01-1994 4-02-1996		Suzuki et al.		
	3	5,504,090	4-02			Neely, C.F.		
	4	5,733,916	3-31	1-1998		Neely, C.F.		
	5	5,932,557	8-03	3-1999		Mustafa et al.		
	6	6,001,842	12-1	14-1999		Neely, C.F.		
	7	6,117,445	9-12	2-2000		Neely, C.F.		
	8	2002/0111333 A1	8-15	5-2002		Lin et al		
	9	2003/0212082 A1	11-1	13-2003		Linden et al.		
	10	2004/0110774 A1	6-10)-2004		Wilson, C.N.		
		FC	DREI	GN PATEN	T De	OCUMENTS	•	•
. Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind C (if known)	_	Publication I MM-DD-YY		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
-	11	JP 9216883A		8-19-1997		Kuroda et al.		Abstract only
	12	WO 98/03507		1-29-1998		Akahane et al.		
	13	WO 99/67239 A1		12-29-199	9	Akahane et al.		
***	14	WO 01/34610 A1		5-17-2001		Kiesman et al.		
	15	WO 03/028730 A2		10-04-200		Novartis AG		
				THER DO				
Examiner Initials*	Cite No.		or (in CAPITAL LETTERS), title of the article (when appropriate), title of symposium, catalog, etc.), date, page(s), volume-issue number(s), publish.			English Language Translation Attached		
ALI, et al., "Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Alle Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Edenosine A ₁ Receptor," The Jour Pharmacology and Experimental Therapeutics, 1993, pp. 1328-1334, Vol. 268(3).		_						
ANGULO, et al., "A ₁ Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation," <i>Brain Pathol.</i> 2003, -pp. 440-451.								

Examiner	Date
Signature	Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/780,296	
			CIIDE	Filing Date	February 17, 2004	
				First Named Inventor	Wilson	
				Group Art Unit	1624	
			1	Examiner Name	M. Berch	
Sheet	2	of	3	Attorney Docket Number	049542/283879	

	U. S. PATENT DOCUMENTS	
18	ASLANIAN, et al., "Cardiovascular and Pulmonary Diseases," Annual Reports in Medicinal Chemistry, 2001, pp. 32-40, Vol. 36(II), Academic Press, San Diego, CA.	
19	BALL, et al., "Clinical Potential of Respirable Antisense Oligonucleotides (RASONs) in Asthma," Am. J. Pharmacogenomics, 2003, pp. 97-106, Vol. 3(2).	
20	BERTI, et al., "Pharmacological Activity of Bamifylline on Lung Anaphylaxis: In Vitro Studies," Pharmacological Research, 1990, Vol. 22(2).	
21	CRONSTEIN, et al., "Neutrophil Adherence to Endothelium is "Enhanced Via Adenosine A ₁ Receptors and Inhibited Via Adenosine A ₂ Receptors," The Journal of Immunology, 1992, pp. 2201-2206, Vol. 148.	
22	CRONSTEIN, et al., "The Adenosine/Neutrophil Paradox Resolved: Human Neutrophils Possess Both A1 and A2 Receptors that Promote Chemotaxis and Inhibit O ₂ Generation, Respectively," J. Clinic. Invest., 1990, pp. 1150-1157, Vol. 85.	
23	DAR, M.S. et al., "Acute Ethanol / Cannabinoid-Induced Ataxia and Its Antagonism by Oral/Systemic/Intracerebellar A ₁ Adenosine Receptor Antisense in Mice," <i>Brain Research</i> , 2002, pp. 53-60, Vol. 957.	
. 24	FORMAN, et al., "Sustained Reduction in Myocardial Reperfusion Injury with an Adenosine Receptor Antagonist: Possible Role of the Neutrophil Chemoatractant Response," The Journal of Pharmacology and Experimental Therapeutics, 2000, pp. 929-938, Vol. 292(3).	
25	GASPARDONE, et al., "Bamiphylline Improves Exercise-Induced Myocardial Ischemia Through a Novel Mechanism of Action," Circulation, 1993, pp. 502-508, Vol. 88(2).	
26	GAUBERT, Yves, "Clinical Experience with a New Antispasmodic," <i>Journal De Medicine De Bordeaux</i> , May 1967, pp. 772-776, Vol. 5.	
27	GOTTLIEB, S.S., et al., "BG9719 (CVT-124), an A ₁ Adenosine Receptor antagonist, Protects Against the Decline in Renal Function Observed with Diuretic Therapy," <i>Journal of American Heart Association</i> , 2002, pp. 1348-1353.	
28	MARONE, G., et al., "Adenosine Receptors on Human Leukocytes IV. Characterizaton of an A ₁ /R ₄ Receptor," Int. J. Clin. Lab. Res., 1992, pp. 235242, Vol. 22.	
29	MARONE, G., et al., "Adenosine Receptors on Human Inflammatory Cells ¹ ," Int. Archs Allergy appl. Immun., 1985, pp. 259-263, Vol. 77.	**************************************
30	MAYNE, M., et al., "Dysregulation of Adenosine A1 Receptor-Mediated Cytokine Expression in Peripheral Blood Mononuclear Cells from Multiple Sclerosis Patients, American Neurological Association, 1999, pp. 633-639.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Examiner	Date	
Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005)				Complete if Known		
				Application Number	10/780,296	
INFOD	NA A TION	I DISCLO	CIIDE	Filing Date	February 17, 2004	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			First Named Inventor	Wilson	
				Group Art Unit	1624	
(Use as many sheets as necessary))	Examiner Name	M. Berch	
Sheet	3	of	3	Attorney Docket Number	049542/283879	

	U. S. PATENT DOCUMENTS	
31	NEELY, C.F. et al., "A ₁ Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Lung," American Physiological Society, 1995, pp. L1036-L1046.	
32	NEELY, C.F. et al., "A ₁ Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Heart," American heart Association, Inc., 1996, pp. II-376-II-380.	
33	NEELY, C.F. et al., "A ₁ Adenosine Receptor Antagonists Block Endotoxin-Induced Lung Injury," American Physiological Society, 1997, pp. L353-L361.	
34	MCCOY, D.E., et al., "Identification and Function of A ₁ Adenosine Receptors in Normal and Cyctic Fibrosis Human Airway Epithelial Cells," American Physiological Society, 1995, pp. C1520-C1527.	
35	OBIEFUNA, P.C.M., et al., "A Novel A ₁ Adenosine Receptor Antagonist, L-97-1 [3-[2-(4-Aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], Reduces Allergic Responses to House Dust Mite in an Allergic Rabbit Model of Asthma," The Journal of Pharmacology and	
36	PANTHER, E., et al., "Expression and Function of Adenosine Receptors in Human Dendritic Cells," The FASEB Journal, 2001, pp. 1963-1970, Vol. 15.	
37	SALMON, J.E., et al., "Human Mononuclear Phagocytes Express Adenosine A ₁ Receptors," The Journal of Immunology, 1993, pp. 2775-2785.	
38	SANTOS, J.M., et al. "Clinical Experimentation with AC 3810 (Trentadil)," Publicado en la Revista Medicina, August 1964, Vol. 8.	
39	SATOH, A., et al., "Activation of Adenosine A ₁ -Receptor Pathway Induces Edema Formation in the Pancreas of Rats," American Gastroenterological Association, 2000, pp. 829-836, Vol. 119.	
40	VARANI, K., et al., "Alteration of Adenosine Receptors in Patients with Chronic Obstructive Pulmonary Disease," Am J. Respir Crit Care Med, 2005, pp. 398-406, Vol. 173.	
41	WEISBERG, S.P., et al., "Adenosine Receptor Antagonists Inhibit the Development of Morphine Sensitization in the C57BL/6 Mouse," Neuroscience Letters, 1999, pp. 89-92.	
42	WILSON, C.N., et al., "Lipopolysaccharide Binds to and Activates A ₁ Adenosine Receptors on human Pulmonary Artery Endothelial Cells," <i>Journal of Endotoxin Research</i> , 2002, pp. 1-9, Vol. 8.	***************************************

RTA01/2194750v1

_			
Γ	Examiner	Date	
	Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.